Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Genes (Basel) ; 15(5)2024 05 04.
Artigo em Inglês | MEDLINE | ID: mdl-38790213

RESUMO

MicroRNAs (miRNAs) are a class of small non-coding RNAs that may function as tumor suppressors or oncogenes. Alteration of their expression levels has been linked to a range of human malignancies, including cancer. The objective of this investigation is to assess the relative expression levels of certain miRNAs to distinguish between prostate cancer (PCa) from benign prostatic hyperplasia (BPH). Blood plasma was collected from 66 patients diagnosed with BPH and 58 patients with PCa. Real-time PCR technology was used to evaluate the relative expression among the two groups for miR-106a-5p and miR-148a-3p. The significant downregulation of both miRNAs in plasma from PCa versus BPH patients suggests their potential utility as diagnostic biomarkers for distinguishing between these conditions. The concurrent utilization of these two miRNAs slightly enhanced the sensitivity for discrimination among the two analyzed groups, as shown in ROC curve analysis. Further validation of these miRNAs in larger patient cohorts and across different stages of PCa may strengthen their candidacy as clinically relevant biomarkers for diagnosis and prognosis.


Assuntos
Biomarcadores Tumorais , MicroRNAs , Hiperplasia Prostática , Neoplasias da Próstata , Humanos , Masculino , MicroRNAs/genética , MicroRNAs/sangue , Neoplasias da Próstata/genética , Neoplasias da Próstata/diagnóstico , Neoplasias da Próstata/sangue , Biomarcadores Tumorais/genética , Biomarcadores Tumorais/sangue , Idoso , Pessoa de Meia-Idade , Hiperplasia Prostática/genética , Hiperplasia Prostática/sangue , Hiperplasia Prostática/diagnóstico , Projetos Piloto , Regulação Neoplásica da Expressão Gênica
2.
Med Pharm Rep ; 93(4): 390-395, 2020 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-33225265

RESUMO

BACKGROUND AND AIMS: In patients with recurrent high grade or muscle-invasive bladder cancer and concomitant upper urinary tract tumors or non-functional kidney laparoscopic radical cystectomy and nephroureterectomy with lomboaortic and pelvic lymph node dissection can be performed. We present our initial experience. METHODS: Between 2018 and 2019, 4 patients underwent laparoscopic radical cystectomy and unilateral nephroureterectomy en bloc resection with lomboaortic and pelvic lymph node dissection. The nephroureterectomy was the first part of the surgery. It was followed by radical cystectomy with lymphadenectomy. All the specimens were removed en bloc in an endobag through a midline incision. RESULTS: The patients' demographic characteristics and perioperative outcomes were retrospectively collected and evaluated. All surgeries were completed laparoscopically. There was no need for conversion to open surgery. The mean operative time was 286,25 min with minimal blood loss (260 ml). No major complications were reported. The mean follow-up period was 8.75 months. CONCLUSION: Laparoscopic radical cystectomy and nephroureterectomy en bloc resection with lomboaortic and pelvic lymph node dissection can be safe and feasible in selected cases as an alternative approach to the open surgery, offering good oncological and functional results.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...